Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism - Erem,C.; Kocak,M.; Nuhoglu,I.; Yilmaz,M.; Ucuncu,O. (Eur J Endocrinol, 2009)